Search Research Articles
Browse Research Categories

Mazdutide Peptide Research

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor co-agonist peptide developed by Innovent Biologics, studied for its combined incretin and glucagon signaling approach to metabolic disease and obesity management. By activating both receptors simultaneously, Mazdutide research has explored its ability to deliver enhanced weight loss compared to GLP-1 monotherapy — with the glucagon component driving additional energy expenditure, fat oxidation, and hepatic lipid clearance. Clinical studies have investigated its applications in obesity, type 2 diabetes, and non-alcoholic fatty liver disease, where dual-axis activation may offer distinct advantages. This section covers current research on Mazdutide and its dual-agonist metabolic and peptide research applications.

Other Popular Research Categories

Newest Mazdutide Research

Mazdutide Peptide Research – Complete Guide

Mazdutide is a synthetic peptide analog of oxyntomodulin that simultaneously activates two receptors — the GLP-1 receptor and the glucagon receptor — producing complementary effects on glucose control, appetite suppression, and fat metabolism. Originally developed by Eli Lilly and now advanced by Innovent Biologics, mazdutide has completed multiple Phase 3 trials showing body weight reductions up to 20% and superior...

About The Cenexa Labs Research Library

This section of the research library focuses on scientific studies involving and related research. The Cenexa Research Library compiles publicly available scientific literature and research summaries related to peptides, bioregulators, and signaling molecules. Our goal is to make complex scientific research easier to understand without requiring a technical background.
Scroll to Top
0